Digitalhealthcareforrespiratorydisease

TonyKea)ngChiefExecu)veOfficerandManagingDirector

tony@resapphealth.com.au

TechKnowInvestRoadshowOctober2016

ASX:RAP

For

per

sona

l use

onl

y

DisclaimerThispresenta)onhasbeenpreparedbyResAppHealthLimited(“ResApp”).Theinforma)oncontainedinthispresenta)onisaprofessionalopiniononlyandisgiveningoodfaith.Certaininforma)oninthisdocumenthasbeenderivedfromthirdpar)esandthoughResApphasnoreasontobelievethatitisnotaccurate,reliableorcomplete,ithasnotbeenindependentlyauditedorverifiedbyResApp.Anyforward-lookingstatementsincludedinthisdocumentinvolvesubjec)vejudgmentandanalysisandaresubjecttouncertain)es,risksandcon)ngencies,manyofwhichareoutsidethecontrolof,andmaybeunknownto,ResApp.Inpar)cular,theyspeakonlyasofthedateofthisdocument,theyassumethesuccessofResApp’sstrategies,andtheyaresubjecttosignificantregulatory,business,compe))veandeconomicuncertain)esandrisks.Actualfutureeventsmayvarymateriallyfromtheforward-lookingstatementsandtheassump)onsonwhichtheforward-lookingstatementsarebased.Recipientsofthisdocument(Recipients)arecau)onedtonotplaceunduerelianceonsuchforward-lookingstatements.ResAppmakesnorepresenta)onorwarrantyastotheaccuracy,reliabilityorcompletenessofinforma)oninthisdocumentanddoesnottakeresponsibilityforupda)nganyinforma)onorcorrec)nganyerrororomissionwhichmaybecomeapparentaZerthisdocumenthasbeenissued.

Totheextentpermi[edbylaw,ResAppanditsofficers,employees,relatedbodiescorporateandagents(Agents)disclaimallliability,direct,indirectorconsequen)al(andwhetherornotarisingoutofthenegligence,defaultorlackofcareofResAppand/oranyofitsAgents)foranylossordamagesufferedbyaRecipientorotherpersonsarisingoutof,orinconnec)onwith,anyuseorrelianceonthispresenta)onorinforma)on.

Thispresenta)onisnotanoffer,invita)on,solicita)onorrecommenda)onwithrespecttothesubscrip)onfor,purchaseorsaleofanysecurity,andneitherthispresenta)onnoranythinginitshallformthebasisforanycontractorcommitmentwhatsoever.

AllamountsinAustraliandollarsunlessstatedotherwise.

2

For

per

sona

l use

onl

y

Digitalhealthcareforrespiratorydisease§  Developingtheworld’sfirstclinically-tested,regulatory-approvedrespiratorydisease

diagnos)ctestandmanagementtoolsforsmartphones-  Noaddi'onalhardwareneeded

§  Hugeglobalmarket,700M+doctorvisitsannuallyforrespiratorydisease1

-  Uniqueopportunitytointegrateintotelehealthproviders’exis)ngplaborms-  Strongdemandalsoseenwithinclinics,emergencyroomsandoutpa)entfacili)es

§  Compellingclinicalevidencewith1,800+pa)entsenrolledinpediatricandadultstudies§  SuccessfulPre-Submissionmee)ngheldwithUSFDA,targe)ngUSapprovalinH12017§  PediatricUSFDAregistra)onstudytobeginshortlyatleadingUShospitals§  Strongbalancesheetwith$13.7Mcash

31.ResAppes)matebasedonOECDdoctorvisitspercapitadataandassuming10%ofvisitsareforrespiratorydisease(basedonUSdata)

For

per

sona

l use

onl

y

Companyoverview

4

CapitalStructure(ASX:RAP)MarketCap. $307M

SharePriceasof14October2016

$0.47

SharesonIssue1 653M

PerformanceShares2 93.75M

Op)ons3 12.8M

StaffIncen)veOp)ons4 31M

CashBalanceasof30June2016

$13.7M

1.  Includes59.6Mescrowedshares(un)l14/7/17)2.  Issuedonachieving$20Mofannualrevenueoronanacquisi)on3.  6.4M,exercisepriceof2.6c,expire31/12/16;4.5M,exercisepriceof

28c,expire29/4/19;1.87M,exercisepriceof30c,expire29/4/194.  Issuedtostaffandscien)ficadvisoryboard

BoardofDirectorsDrRogerAston Non-Execu)veChairman(ChairmanofOncosilMedicalLtd,formerlyCEOofMaynePharma,CambridgeAn)body,co-founderofpSividaCorp.)

DrTonyKea)ng ManagingDirectorandCEO(formerlyDirector,CommercialEngagementofUniQuest,engineeringmanagementroleswithExaCorpora)on)

MrBrianLeedman Execu)veDirectorandVP(ChairofAusBiotech-WA,Non-Execu)veDirectorofAlcidionLtd,co-founderofImugeneLtdandOncosilMedicalLtdandformerlyVP,IRatpSividaCorp.)

MrChrisNtoumenopoulos Non-Execu)veDirector(ManagingDirectoratTwenty1Corporate,Non-Execu)veDirectoratRaceOncology,formerlyatCi)group,IndianOceanCapitalandCPSCapital)

Substan)alShareholdersFreemanRoad:6.84%FidelityInterna)onal:6.15%F

or p

erso

nal u

se o

nly

Diagnosisofrespiratorydiseaseisthemostcommonoutcomefromavisittothedoctor

5

Acutecondi'onsURTIs,influenza,bronchi)s,bronchioli)s,pneumonia,pertussis,croupChronicCondi'onsAsthma,COPD,cys)cfibrosis,bronchiectasis

§  700M+doctorvisitsp.a.globally1forrespiratorydisease→  125MinUS2(10%ofallvisits)→  6-8MinAustralia3

§  US$10.5Bp.a.UShospitalcostsforpneumonia4

§  HighprevalenceandgrowthinAsia

1.ResAppes)matebasedonOECDdoctorvisitspercapitadataandassuming10%ofvisitsareforrespiratorydisease(basedonUSdata)2.Ambulatorycasevisits,Na)onalAmbulatoryMedicalCareSurvey20103.AustralianLungFounda)on4.HCUPSta)s)calBrief#160

Currentlydiagnosedusingstethoscope,imaging(x-ray,CT),bloodand/orsputumtests➝Timeconsuming,expensiveandnotveryaccurate

For

per

sona

l use

onl

y

Easytouse,instantdiagnosisusingonlyasmartphone§  Exclusiveworldwidelicensetomachinelearning

technologydevelopedbyAssociateProfessorUdanthaAbeyratneatTheUniversityofQueensland

§  Usessignaturesincoughsoundstodiagnosedisease§  Ini)aldevelopmentfundedbyTheGatesFounda)onto

reducethe1Mchilddeathsp.a.duetopneumoniainthedevelopingworld

§  Patentapplica)onfiledinUS,Australia,Europe,China,JapanandSouthKorea

§  Usesthemicrophonesintoday’ssmartphones

→ Noaddi'onalhardwarerequired

6

For

per

sona

l use

onl

y

Verifiedbycompellingpediatricclinicalevidence

7

2013Study Sensi'vity Specificity Accuracy

Pneumoniavs.allrespiratory1 94% 100% 96%

Asthmavs.pneumonia2 100% 80% 90%

1.  Abeyratneetal.,AnnalsofBiomedicalEngineering,20132.  Kosashietal.,IEEETransac)onsinBiomedicalEngineering,20153.  ResAppPressRelease30September2015,211subjectdataset4.  ResAppPressRelease10November2015,338subjectdataset5.  ResAppPressRelease31March2016,524subjectdataset

2015StudyPreliminaryResults Sensi'vity Specificity Accuracy

Pneumoniavs.norespiratory4 100% 95% 97%

Asthmavs.norespiratory3 97% 92% 95%

Bronchioli'svs.norespiratory4 100% 100% 100%

Croupvs.norespiratory4 94% 100% 99%

URTIvs.norespiratory4 100% 95% 96%

Pneumonia,crouporbronchioli'svs.URTI4 89-100% 90-95% 89-98%

Differen'aldiagnosisofpneumonia,croup,URTIandbronchioli's5

91-99% 89-98% 89-98%

2013PediatricProof-of-ConceptStudy

SardijtoHospital,Indonesia

91pediatricpa)entsenrolled

2015/16AustralianPediatricStudy

976pediatricpa)entsenrolledtodate

JoondalupHealthCampusandPrincessMargaretHospital

FundedbytheBillandMelindaGatesFounda)on

LatestresultsreleasedMarch2016Enrolmentandanalysiscon)nuing

For

per

sona

l use

onl

y

Buildingstrongclinicalevidenceinadults

8

AdultStudyPreliminaryResults Sensi'vity Specificity Accuracy

COPDvs.norespiratory 100% 96-100% 98-100%

Asthmavs.norespiratory 91% 91-93% 91-92%

Pneumoniavs.norespiratory 97-100% 100% 98-100%

URTIvs.norespiratory 100% 100% 100%

AsthmaorCOPDvs.norespiratory 91-93% 91-93% 91-93%

Asthmavs.COPD 93% 96% 94%

Pneumoniavs.Asthma 92% 81% 88%

Pneumoniavs.COPD 92% 92% 92%

2015/16AustralianAdultStudyJoondalupHealthCampusandWesleyHospital772adultpa)entsenrolledtodate

LatestresultsreleasedOctober2016Enrolmentandanalysiscon)nuing

1.  ResAppPressRelease3October2016

For

per

sona

l use

onl

y

Achievingbreakthroughperformanceindiagnosis§  Lowerrespiratorytractdiseasediagnosis

-  Effec)vetreatmentneedsiden)fica)onoflowerrespiratorytractinvolvement-  Correctlydetectedlowerrespiratorytractinvolvementin97%ofcasesini'ally“missed”by

experiencedcliniciansusingastethoscope

§  Causeofpneumoniadiagnosis“Weneedfaster,less-expensivediagnos@ctestsfordoctorstoaccuratelydiagnosethe

causeofpneumoniasotheycaneffec@velytreatit”USCDC(2015)1-  Incorrectdiagnosisleadstounnecessaryandineffec)vean)bio)cuse-  Iden)fyingthecausetodayis)meconsuming,costlyandonlyavailableinter)aryhospitals-  Preliminaryresultsdemonstratedsepara'onofbacterialandatypicalfromviralpneumoniawith

89%and90%accuracy

91.  USDepartmentofHealthandHumanServicesPressRelease,Feb25,2015

(h[p://www.cdc.gov/media/releases/2015/p0225-pneumonia-hospitaliza)ons.html)

For

per

sona

l use

onl

y

Uniqueopportunitytodeployalongsidetelehealth,oneofthefastestgrowingtrendsinhealthcare§  UStelehealthisalreadylarge,andgrowingrapidly§  Telehealthbenefitsall:payors,pa)entsandhealthcareproviders

§  30-50%oftelehealthconsultsforrespiratorydisease4,noaccurateremotediagnosisavailable§  ResApp’stestcanbedeliveredanywhere,any'mewhileretainingaclinician’sinput

10

75Mconsultsp.a.

(UStelehealth‘evisits’in2014es)matedbyDeloi[e)1

US$12BUSTAM

(GoldmanSachsUStotaladdressablemarketes)mate)3

56%growth

(Growthrateun)l2018es)matedbyIHS)2

1. Deloi[e,eVisits:the21stcenturyhousecall(August2014)2. IHS,WorldMarketforTelehealth(2014)3. GoldmanSachsEquityResearch,TheDigitalRevolu)onComestoUSHealthcare(June2015)4. Uscher-PinesandMehrotra(HealthAffairs,2014)andUnitedHealthcarePresenta)on

For

per

sona

l use

onl

y

Pursuingatrulyglobalopportunity§  SignificantgrowthintelehealthinEuropeandAustralia

-  PlantofileforCEMarkinearly2017inparallelwithFDAsubmission

§  Hugepoten)alinAsiaPacificwherethereareover1billionsmartphoneusers1

-  Highprevalenceofrespiratorydiseaseandna)onwideshortageofdoctorsinChina2

-  Chinesemobileonlineconsulta)onexamples:

§  Ac'vepartnershipdiscussionsinallregions

111. ForresterResearch2. “DearthofDoctorsinChinaSaidtoPutChildren’sHealthatRisk,CaixinOnline,h[p://english.caixin.com/2016-01-21/100902234.html

92Mac)veusers229ques)onsperminute

Chunyuyisheng PingAnHaoyisheng

25Mac)veusers95,000appointmentsperday

For

per

sona

l use

onl

y

Targe)ngmul)plemarketsegments

12

Telehealth Clinicaluse Developingworld Directtoconsumer

Marketsize

• 22.5Mrespiratory-relatedUStelehealthconsultsp.a.

• 13.4MUSEDvisitsforrespiratorydiseasep.a.1(~4.6Mforchildren)

• 1Mchilddeathsduetopneumoniap.a.3• 151Mcasesofpneumoniaindevelopingcountriesp.a.3

• 400MiPhoneusers4• 1.6BAndroidusers4• mHealthappmarketexpectedtogrowto$25Bbyendof20175

Valueproposi'on

✓  Theonlyremoteclinically-accuratediagnos)ctoolavailable

✓  Easilyintegratedintoexis)ngplaborms

✓  Reducecosts(<$10vs>$200forx-ray)

✓  Reduce)me(x-rayadds~30mins,culturescantakedays)

✓  Lowcost,accurate&fast✓  Usablebynon-medical

personnel✓  IntegratesintoIMCI

framework

✓  Convenience✓  Lowcost✓  Consumer

empowerment

Commercialstrategy

Partnerwithtelehealthproviderstoreach10sofmillionsofpa)ents

Ini)aluseinemergencydepartments(ED),extendingtoregularclinics

Partnerwithleadinginterna)onalaidagenciestoequipfieldpersonnel

Directtoconsumerviaappstorestotargetgrowthinconsumer-ledhealth

Revenuemodel B2Bpertestfee(<$10)fromtelehealthproviders

B2Bpertestfee(<$10)fromhealthcarepayors

B2Bannualsubscrip)onfromaidagencies

B2Cdownloadandpertestfeedirectfromconsumers

1. ResAppes)matebasedonOECDpercapitadata2. NHAMCS(2011)3. WHOes)mate

4. Sta)sta(2014es)mates)5. Research2guidancemHealthAppDeveloperEconomics(2014)

700MdoctorvisitsinOECDforrespiratorydiseasep.a.1

For

per

sona

l use

onl

y

Improvingchronicrespiratorydiseasemanagement§  334Mpeoplehaveasthma1

-  17.7MinUS2,30MinEurope3,2.3MinAustralia4

-  $30B+p.a.USeconomicburden2

-  Pa)entadherencetoasthmamedica)onsisgenerallyverypoor

§  65MpeoplehavemoderatetosevereCOPD5

-  Emphysemaandchronicbronchi)s,primarycausedbysmoking-  3M+peoplediedofCOPDin2012,6%ofalldeathsglobally5

§  HighprevalenceofasthmaandCOPDinChina

§  OpportunitytomeasuretheseverityofasthmaandCOPD,withoutthecostofaddi)onalhardwareortheneedtocarryanextradevice

§  ExploratoryclinicalstudiesunderwayatJoondalupHealthCampusandtheWesleyHospital

13

1. TheGlobalAsthmaReport2014(GlobalAsthmaNetwork)2. USCDC3. EuropeanLungWhiteBook4. AsthmaAustralia

5. WHO6. Interna)onalStudyofAsthmaandAllergiesinChildhood7. COPDFounda)on

1in7childrenhasasthma6

1in5adultsover45hasCOPD7

For

per

sona

l use

onl

y

PivotalmilestonesleadinguptofirstFDAapproval

14

H22016¨  Clinicalcollabora)onsforasthmaandCOPD

management¨  Addi)onalAustralianadultstudyresults¨  Startfieldevalua)onwithhumanitarianorg.¨  StartSMARTCOUGH-C,pivotalUSpediatricstudy¨  Addi)onalAustralianpediatricstudyresults

H12017¨  Addi)onalAustralianadultstudyresults¨  StartpivotalUSadultclinicalstudy¨  PrimarydatafromSMARTCOUGH-C¨  FiledenovopremarketsubmissionwithFDAfor

leadResAppproduct(pediatric)¨  FileforCEMarkinEurope¨  FDAmarke)ngapprovalforleadResAppproduct

✓

✓

SMARTCOUGH-CstudyProspec)ve,mul)-site,double-blindstudywithprimaryendpointsofdiagnosisofchildhoodpneumonia

SecondaryendpointsofdiagnosisofURTI,croup,bronchioli)s,asthma/viralwheezeandlowerrespiratorytractinvolvement

ThreeconfirmedUSsites:1.  Massachuse[sGeneralHospital2.  Unnamed,top-)eracademicmedicalcenter3.  Unnamed,top-)erchildren’shospital

SupportedbyINCResearch,agloballeadingCRO

✓

For

per

sona

l use

onl

y

Summary§  Revolu)onarytechnology–diagnosisandmanagementofrespiratorydiseasewithouttheneedforaddi)onalhardware

§  Compellingclinicalevidence-  Veryhighaccuracyfrommul)pleadultandpaediatricclinicalstudies,over1,800pa)entsenrolledtodate-  Breakthroughresults:Detec)nglowerrespiratorytractinvolvementwhichmaybemissedbyausculta)onand

diagnosingthecauseofpneumonia(viral,bacterialoratypical)

§  ClearUSregulatorypathway-  HeldsuccessfulUSFDAPre-Submissionmee)nginQ12016-  ConfirmeddenovoregulatorypathwayasClassIIMedicalDevice-  CommencingpivotalUSclinicalstudy,SMARTCOUGH-C,attop-)erhospitalstosupportdenovosubmission

§  USmarketentryin2017-  LaunchviaUStelehealthpartnertoreachmillionsofpa)entsquickly-  Poten)alEuropean,AustralianandAsianmarketentryinparalleltoUS-  Deploymenttolowresourceareasviapartnershipswithhumanitarianorganisa)ons

15

For

per

sona

l use

onl

y